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may help address some of the infectious complications of
BMT, an approach that is being tested in clinical trials. The
fact thatMP can be cryopreserved and can be used effectively
without being MHC matched to the host enables this
approach.
We have reported in preclinical models that we can use MP
to induce speciﬁc and lasting tolerance for solid organ
transplants. In our model, mice (typically BALB/c) are pre-
conditioned and reconstituted with autologous or allogeneic
hematopoietic stem cells (HSC) and allogeneic MP. MP-
matched skin grafts are placed simultaneously and their fate
is followed long-term. We have established that MP induce
speciﬁc tolerance, MP-matched skin grafts are accepted,
while grafts unmatched to the MP, HSC or host are rejected.
MP from Rag2-/-IL2rg-/- mice that are incapable of produc-
ing B cells, T cells or NK cells, establish that only organ-graft
matched myeloid cells are essential for this process. Toler-
ance can be induced by 100,000 MP in the context of allo-
geneic (third party) HSC transplantation. However, we have
previously reported that the same number of MP only pro-
tects skin grafts in approximately 80% of the recipients that
have been given autologous HSC (Transpl Immunol 31:112-
118,2014).
Here we report that while tolerance induction byMP is more
efﬁcient when combined with allogeneic HSC, increasing the
cell dose ensures the same outcome with autologous HSC.
Injection of 40,000 or more Linneg/lo, Sca-1neg, c-Kit+ MP
induces robust tolerance in recipients of allogeneic HSC.
However, similar results can be obtained in the context of
host-autologous HSC by using slightly higher cell doses
(200,000 or more MP are needed to protect all skin grafts).
We conclude that organ matched MP can induce robust
tolerance for simultaneously or subsequently placed solid
organ transplants, without the need for long-term high level,
multi-lineage engraftment. The speciﬁc properties of MP
(they are clinically available, they can be cryopreserved, they
can be used without matching and MP can be expanded ex
vivo) makes these cells of particular interest. They offer a
new approach to the use of BMT to help in improving solid
organ transplantation.398
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Purpose: Vitamin D deﬁciency has been associated with
chronic Graft Versus Host Disease (GVHD), and insufﬁcient
Vitamin D levels have been shown in patients who have
undergone hematopoietic cell transplant (HCT). This pilot
study tests the hypothesis that Vitamin D deﬁciency is
prevalent and is associated with acute GVHD (AGVHD) in the
immediate 90 days after HCT.
Methods: Fifty allogeneic subjects were selected from the
HCT database based on available bio-samples pretransplant,
30 days, and 90 days post HCT, obtained during 2012-2013.
Retrospective clinical data were also obtained. Liquidchromatography-tandem mass spectrometry (LC-MS/MS)
was used to determine 25-OH vitamin D (D2, D3 and total)
levels at the three time-points. Descriptive analysis was
completed using PASW (IBM, V.20).
Results: 50 subjects (25 male, 25 female), mean age 4111
years, 48% white (18% Asian, 34% other), were selected.
AGVHDwas present in 23/49 (w50%) of subjects and 73% had
Vitamin D deﬁciency at baseline (208 ng/ml), signiﬁcantly
decreasing at 30 days (168 ng/ml, p¼.048), and remained
constant at 90 days (1610 ng/ml). Majority of samples were
below threshold for Vitamin D (<25 ng/ml, 77%), however no
signiﬁcant relationship to AGVHDwas detected (p¼.530). For
sex, men had greater proportion with low Vitamin D (83% v
63%) and AGVHD (52% v 42%) than women, though not
reaching signiﬁcance (p¼.193 & p¼.571). For race, all Asian
subjects were below threshold for Vitamin D (9/9) and 4
developed AGVHD (44%).
Conclusion: We identify a signiﬁcant majority of subjects
undergoing HCT have Vitamin D deﬁciency (73%), progress-
ing 30 days post HCT with a disproportionate effect on sex
and race. Although we do not detect an association between
Vitamin D deﬁciency and AGVHD, an appropriately powered
study is needed to determine whether a relationship exists.
Supplementation andmonitoring HCT patients for Vitamin D
deﬁciency is warranted.399
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Regulatory T cell (Treg) therapy provides an alternative
approach to chronic immunosuppression and has shown
promising results in murine models. Translating this
approach into the clinic depends on developing efﬁcient
methods with which to expand human or non-human pri-
mate Tregs in vitro.
At the Columbia Center for Translational Immunology (CCTI)
we have started a pre-clinical bone marrow transplant pro-
gram using the Cynomolgus macaque (CM) monkey model
involving Tregs to promote tolerance to tissues and organs.
We ﬁrst characterized CM Tregs, which have similar
phenotype when compared to human Tregs. 3.67% of CD4 T
cells in the CM co-express high levels of CD25 and FoxP3
(n¼15) and 3.53% express CD25 and are negative for CD127, a
commonly used Treg marker. Similar to human Tregs, CM
Tregs include naïve or resting Tregs (1.63%) and activated
effector Tregs (2.4%) based on CD45RA expression (n¼7). In
vitro CM CD25hiCD127- (FoxP3+) Tregs were found to be
similarly suppressive as human Tregs, supporting the clinical
relevance of the CM model.
We subsequently aimed to expand polyclonal regulatory T
cells (pTregs) in vitro for use in our transplant studies. We
developed four protocols for the expansion of pTregs over
21-56 days. 50-100 thousand CD4+CD8-CD25hi or CD4+CD8-
CD25hiCD127- Tregs were isolated from 20-30mL of blood
and cultured with IL-2, aCD3, rapamycin and either donor
PBMCs, artiﬁcial APCs (L-cells, murine ﬁbroblast expressing
human CD80, CD58 and CD32) or both. 1000-10,000 fold
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used. In contrast, when donor PBMCs (without artiﬁcial
APCs) were used as the source of APCs, 10-100 fold fewer
Tregs were obtained. Regardless of protocol, pTregs suc-
cessfully prevented the proliferation of bead (CD2CD3CD28)
stimulated self PBMCs with up to 50% suppression at a 1:32
ratio of Tregs:PBMCs.
Contamination of CD8+ T cells was observed despite our ef-
forts to gate out CD8 cells during sorting. Re-sorting of the
Treg cultures early (day 14-21 post isolation) successfully
eliminated the CD8s. Re-sorting inherently caused a signiﬁ-
cant loss of Tregs, leading to a longer culture period. Because
Treg burnout was of concern, we assessed the function and
phenotype of cells maintained in cultures >50 days and
observed that Tregs with early high FoxP3 expression
maintained function and phenotype.
Finally, demonstration of ﬁtness of cryopreserved pTregs is
necessary for clinical application. Our preliminary studies
show that Tregs can be re-cultured and re-expanded without
loss of suppression or phenotype. In summary, we have
successfully established several protocols for Treg expansion
in the Cynomolgus macaque that can be used in pre-clinical
studies of transplant tolerance induction.400
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The impact of early donor cell chimerism on outcomes of
reduced-intensity conditioning SCT inmyeloid disorders is ill
deﬁned. To explore the impact of measuring busulfan phar-
macokinetics (Bu PK) in conditioning regimens on early
donor chimerism, we undertook a retrospective analysis of
patients with myeloid disorders who received four days of
ﬂudarabine and busulfanwith orwithoutmeasuring Bu PK at
our center in the last 10 years.
Methods: Chimerism assay was performed using a quanti-
tative ﬂuorescence-based short tandem repeatepolymerase
chain reaction (STR-PCR) with capillary electrophoresis for
PCR product resolution.
Results: Thirty patients were identiﬁed and included in the
study. All patients received ﬂudarabine (40 mg/m2/day x 4
doses), busulfan (3.2mg/kg/dose IV x 4 doses). Of these thirty
patients, 7 had Bu PK measured. There were 21 male and 9
female patients with a median age of 62 years (range
48e72yrs). Median time to follow up was 13.3 months.
Disease risk was considered advanced in 17 patients, inter-
mediate in 3 and early in 10. All patients in the Bu PK group
had advanced disease except one had early disease.
Regarding cytogenetics, all patients in the Bu PK group had
high or intermediate risk cytogenetics. Median blast number
at time of SCT was 5%. Stem cell source included peripheral
blood in all patients.
There were no primary graft failures. Total Donor cell
Chimerism analysis in the Bu PK group showed 100% donor
at both time points (days 30,100) in all patients except in one
who relapsed at day 30 (85.7%). While in the non-PK grouponly 7 out of 23 (30%) patients had complete chimerism at
day 30 and day 100. Complete donor chimerism at day 100 in
the non-PK group was 47.8% compared to 85.7% in the PK
(p¼0.18). Ten out of 23 patients (43.5%) in the non-PK group
had decreasing donor chimerism by day 100, while in the PK
group only one patient (14%) who relapsed had decreasing
donor chimerism by day 100 with an odds ratio of 0.241 (95%
Conﬁdence Interval¼0.025-2.357; p-value¼0.22). None
developed sinusoidal obstructive syndrome.
Conclusion: In this small cohort from a single center, we
found that patients with myeloid disorders who received
ﬂudarabine busulfan for 4 days incorporating Bu PK had a
trend for higher rates of early complete donor chimerism
and less decreasing donor chimerism by day100 despite
having intermediate or high risk disease at time of SCT.
Longer follow up is needed for our patients to see if there
is effect on relapse or survival but previous studies have
showed that low or decreasing donor chimerism early after
SCT is an independent risk factor for relapse and impaired
survival. This is especially important in myeloid disorders.
Bu PK may help target better level for inducing early total
donor chimerism and donor chimerism may identify high-
risk patient cohorts who may beneﬁt from additional
therapeutic interventions.401
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The female donor/male recipient combination increases the
risks of graft-versus-host disease (GVHD) and non-relapse
mortality (NRM) after allogeneic stem cell transplantation
(allo-SCT). To explore the impact of Female matched related
donor (F-MRD) versus male matched unrelated donor
(M-MUD) on outcome of peripheral blood allo-SCT in male
recipients, we undertook a single center retrospective anal-
ysis of male adult patients transplanted at our center in the
last 10 years. We excluded patients who received donor
lymphocyte infusion post SCT.
Methods: Disease-free survival (DFS) and OSwere calculated
using the Kaplan-Meier estimate. Cumulative incidences (CI)
were used for relapse (REL) and GVHD in a competing risks
setting, NRM being a competing event for REL, and death for
GVHD.
Results: Fifty-six patients were identiﬁed and included in
this analysis. The median age at transplant was 57 years (19-
73). Diseases were AML (n¼21), ALL (n¼7), NHL (n¼9),
Hodgkin’s disease (n¼1), myeloma (n¼5), MDS (n¼11), CLL
(n¼1), and CML (n¼1). Conditioning regimens were mye-
loablative (MAC) (n¼35), reduced toxicity ablative (n¼17) or
non myelablative (n¼4). Donors were F-MRD (n¼24) or
M-MUD (n¼32). Source of stem cells was peripheral blood in
all patients. GVHD prophylaxis consisted of tacrolimus and
methotrexate in MRD and tacrolimus, methotrexate and
anti-thymocyte globulin in MUD. Of the female donors, 63%
had previous pregnancies before donation, 8% had no preg-
nancies and 29% were unknown. Mean age of female donors
was 48 while the mean age for male donors was 35.
